Physician profile
Gillian Collom
NPI 1922873199
$1,064.43
in general payments reported to CMS, 2019-2025
18 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $748 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,064.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $239.39 | 2024-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $144.29 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Corcept Therapeutics | $141.42 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.64 | 2024-2025 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $79.92 | 2024 | |
| Lilly USA, LLC | $72.93 | 2024 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $43.27 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.84 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $39.33 | 2024 | |
| Janssen Biotech, INC. | $28.83 | 2025 | Tremfya |
| Glaxosmithkline, LLC. | $20.98 | 2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $20.88 | 2024 | Veozah |
| Indivior INC. | $19.84 | 2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $18.92 | 2025 | Fanapt |
| Merck Sharp & Dohme LLC | $17.73 | 2024 | Gardasil 9, Gardasil, Capvaxive |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $15.67 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $15.52 | 2024 | Gvoke Hypopen |
| Ironwood Pharmaceuticals, INC | $14.03 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gillian Collom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.